mRNA Vaccines: How the Platform Works for MRNA, BNTX

You keep seeing “mRNA” in headlines. Moderna’s flu vaccine is up for FDA review. BioNTech is running cancer vaccine trials. Both are pivoting beyond COVID. Before you buy MRNA or BNTX, understand the platform, because every drug in their pipelines uses the same core technology. Here is what matters.

The problem

mRNA is the technology behind the fastest vaccine ever developed, the 2023 Nobel Prize in Medicine, and half the pipeline candidates at two of the most-watched biotech companies in the world. But most investors cannot explain what mRNA actually is past “it was in the COVID shot.” That’s a problem, because the investment thesis for Moderna and BioNTech isn’t about one drug. It’s about a platform.

Step 1: Understand the central dogma (DNA → mRNA → protein)

Your cells run on instructions stored in DNA in the nucleus. The central dogma of molecular biology is the flow of information: DNA gets transcribed into mRNA, and mRNA gets translated into proteins. Proteins are the actual functional molecules in your body: enzymes, antibodies, receptors, everything.

mRNA is the messenger. It carries a copy of a gene out of the nucleus to the ribosome, the cell’s protein-making machinery. The ribosome reads the mRNA three letters (a codon) at a time and stitches together amino acids into a protein chain. One gene, one mRNA, one protein. That’s the rule.

An mRNA vaccine hijacks this. Instead of letting the cell use its own DNA, you deliver a synthetic mRNA that encodes a viral protein, a piece of the virus, not the virus itself. The cell makes the viral protein, the immune system sees it, and it builds antibodies and T-cells. The mRNA degrades in a few days, so the instruction is temporary. The immunity isn’t.

Step 2: Know why mRNA needs a lipid nanoparticle

mRNA is fragile. If you inject naked mRNA into a vein, enzymes in the blood shred it in minutes. The molecule is large, negatively charged, and can’t cross the cell membrane on its own.

That vehicle is the lipid nanoparticle (LNP). An LNP is a microscopic bubble of fat molecules that encapsulates the mRNA and gets it into the cell. Four lipid types make up an LNP: ionizable lipids that hold the mRNA and help it escape the cell’s degradation machinery, helper lipids that maintain the particle’s structure, cholesterol for stability, and PEG-lipids that sit on the outside and prevent the particle from clumping.

Here’s the key investor insight: the LNP, not the mRNA sequence, is the hard part. Once you have a working LNP formulation, designing a new mRNA for a new vaccine is essentially changing the code. The delivery technology is the moat. This is why Moderna and BioNTech can pivot from COVID to flu to cancer vaccines: the LNP infrastructure carries over.

Step 3: Understand the Karikó-Weissman breakthrough

For decades, mRNA vaccines failed in trials because the immune system treated the synthetic mRNA as a threat and triggered a massive inflammatory reaction. The vaccine made people sick before it made them immune.

Katalin Karikó and Drew Weissman solved this in the mid-2000s by replacing one of mRNA’s building blocks (uridine) with a modified version called pseudouridine. This single chemical tweak made the mRNA invisible to the innate immune system’s sensors. The cell translated the mRNA into protein without triggering the alarm. This is the discovery that won them the 2023 Nobel Prize in Physiology or Medicine.

Without pseudouridine, mRNA vaccines would still be a lab curiosity. With it, Moderna and BioNTech built multi-billion-dollar platforms. The investor takeaway: modified nucleosides are a platform-level enabler. Any company working on mRNA therapeutics needs to solve this problem, and the Karikó-Weissman approach is now standard.

Step 4: See the platform economics

This is where it gets interesting for investors. Traditional vaccine manufacturing is drug-specific. You grow the virus (or pieces of it), purify it, and formulate it. Each new vaccine needs a new manufacturing process. That’s why flu shots take six months to produce each year.

mRNA manufacturing is different. You synthesize the mRNA strand chemically, wrap it in the same LNP, and you’re done. The manufacturing process is the same whether the mRNA encodes a COVID spike protein, a flu hemagglutinin, or a patient-specific cancer neoantigen. This is the platform argument: build the infrastructure once, produce many drugs.

For investors, this means the pipeline matters more than any single drug. Moderna’s mRNA-1010 flu vaccine has a PDUFA date of August 5, 2026, after a unanimous 9-0 advisory committee vote on June 18. If approved, it validates the platform in a new indication. But the deeper thesis is what comes next: combination vaccines (flu + COVID + RSV in one shot), norovirus, and cancer vaccines.

Step 5: Understand the three pipeline pillars

mRNA drug development falls into three categories:

1. Infectious disease vaccines (flu, RSV, COVID boosters, combination shots). This is the near-term commercial engine. Moderna’s flu vaccine PDUFA is the next catalyst. The economics are high volume, recurring revenue (annual shots), and manufacturing scale.

2. Cancer vaccines (individualized neoantigen therapy), the application with the highest upside. The idea: sequence a patient’s tumor, identify mutations unique to that tumor (neoantigens), design an mRNA that encodes those neoantigens, and deliver it as a vaccine that trains the immune system to attack the cancer. Moderna’s mRNA-4157 (V940) combined with Keytruda showed a 44% reduction in recurrence risk vs. Keytruda alone in the KEYNOTE-942 Phase 2b melanoma trial. BioNTech is running a similar program in pancreatic cancer. For a deeper look at the cancer vaccine thesis, see the Moderna mRNA cancer vaccine analysis. The challenge: these are custom-made per patient, which is expensive and hard to scale.

3. Therapeutics for rare diseases, replacing a missing or defective protein with mRNA that encodes the functional version. This is the earliest-stage pillar. It faces the LNP delivery problem: most approved LNPs go to the liver. Getting mRNA to other organs (brain, muscle, heart) is an unsolved engineering problem.

Step 6: Account for stability and storage

mRNA degrades at room temperature. The original Pfizer/BioNTech COVID vaccine required ultra-cold storage at -70°C. Moderna’s required -20°C. That cold chain requirement was a distribution nightmare and a real commercial constraint.

Formulation improvements have helped. Both companies have extended refrigerator shelf life (2-8°C) from days to weeks for updated COVID vaccines. Lyophilization (freeze-drying) can stabilize mRNA-LNP formulations at refrigerator temperatures for months. But the fundamental instability of mRNA means cold chain logistics remain a cost, especially for individualized cancer vaccines that can’t sit in a warehouse.

For investors, stability improvements reduce distribution costs and expand the addressable market. They also make the platform more competitive against traditional vaccines that are easier to ship and store.

Common mistakes

Treating mRNA as a COVID story. COVID vaccines are the proof of concept, not the endpoint. If you’re evaluating MRNA or BNTX, look at the pipeline beyond COVID. Flu, cancer vaccines, and rare disease therapeutics are where the platform value compounds. For the broader investment case, see the Moderna and BioNTech platform analysis.

Ignoring the LNP delivery problem. Current LNPs deliver mRNA to the liver. That’s fine for vaccines (the immune system is everywhere) and for liver-targeted therapeutics. It’s a problem for anything else. If a company claims an mRNA therapeutic for a brain or heart disease, ask how they’re getting the LNP to that organ. Most can’t, yet.

Assuming cancer vaccines are imminent. The KEYNOTE-942 melanoma data was promising, but it was a Phase 2b trial with 157 patients. Phase 3 is where most biotech drugs fail: roughly one in three Phase 2 successes replicate in Phase 3. The personalized manufacturing model is also unproven at scale. Treat cancer vaccine revenue as a high-risk, multi-year bet, not a near-term catalyst. For a framework on evaluating these risks, see the how-to guide on investing in biotech and how to read clinical trial data without getting fooled by the headline.

Discounting the competition. mRNA isn’t the only platform. Traditional vaccines, protein subunit vaccines, and viral vector vaccines all compete in the same infectious disease markets. Sanofi, GSK, and Pfizer (which has its own flu program outside the BioNTech partnership) all compete with non-mRNA flu programs. The platform advantage is speed and adaptability, not guaranteed dominance.

Final checklist

• You can explain what mRNA does in the cell (DNA → mRNA → protein)
• You understand why the LNP, not the mRNA sequence, is the moat
• You know what pseudouridine modification does and why it won the Nobel
• You can name the three pipeline pillars (infectious disease, cancer vaccines, rare disease)
• You’ve checked which pipeline drugs are in which clinical phase. Early phase means higher risk.
• You understand the cold chain constraint and how it affects commercialization

The mRNA platform is real, and it’s expanding. The technology is the thesis. The execution is the risk.